Novavax, Inc. (NVAX) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Novavax, Inc. (NVAX) trades at a price-to-earnings ratio of 3.9x, with a stock price of $10.14 and trailing twelve-month earnings per share of $2.54.
The current P/E is 24% above its 5-year average of 3.2x. Over the past five years, NVAX's P/E has ranged from a low of 2.4x to a high of 4.9x, placing the current valuation at the 75th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, NVAX trades at a 83% discount to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, NVAX trades at a notable discount to the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NVAX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and Infectious Disease peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
SCNIScinai Immunotherapeutics Ltd. | $3B | 0.1Lowest | -Best | +136% |
NVAXNovavax, Inc. | $2B | 3.9 | -Best | +310%Best |
CVACCureVac N.V. | $1B | 6.5 | -Best | +161% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $6.72 | $2.58 | 2.6x | -18% |
| FY2025 Q3 | $8.67 | $1.77 | 4.9x | +54% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $6.30 | $2.26 | 2.8x | -12% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $6.41 | $2.65 | 2.4x | -24% |
Average P/E for displayed period: 3.2x
See NVAX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVAX Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NVAX vs AGIO
See how NVAX stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NVAX stock overvalued or undervalued?
NVAX trades at 3.9x P/E, above its 5-year average of 3.2x. The 75th percentile ranking indicates a premium to historical valuation.
How does NVAX's valuation compare to peers?
Novavax, Inc. P/E of 3.9x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is NVAX's PEG ratio?
NVAX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2025.